drugset
Drugs / CSL511
last change Oct 2024 re-read 9 days ago

CSL511

also known as Fibrinogen concentrate (human)

Protein / enzyme biologic

Developed for
acquired coagulation factor deficiency
Investigated by
CSL Behring

Trials 1

today NCT06617897 · Ph 3
202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT06617897 Oct 2024 → Sep 2027 expected acquired coagulation factor deficiency CSL Behring Recruiting No outcome recorded

Press releases naming this drug 1 release

DateIssuerRelease
2012-03-15 CSL Behring CSL Behring Announces First Patient Treated in Phase III Study of Fibrinogen Concentrate (Human)(FCH) to Control Bleeding During Aortic Aneurysm Surgery csl.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as CSL511 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06617897 ↗
Known as Fibrinogen concentrate (human) “CSL511 Fibrinogen concentrate (human)” NCT06617897 ↗
Modality Protein / enzyme biologic “CSL511 Fibrinogen concentrate (human)” NCT06617897 ↗
Route Intravenous “CSL511 will be prepared in sterile water for injection and administered as an intravenous (IV) infusion.” NCT06617897 ↗